Septerna to Present at TD Cowen 46th Annual Health Care Conference

Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company specializing in G protein-coupled receptor (GPCR) drug discovery, has announced that its CEO and co-founder, Dr. Jeffrey Finer, will present at the TD Cowen 46th Annual Health Care Conference. The event is scheduled for March 3, 2026, at 3:10 p.m. ET in Boston. Interested parties can access a live webcast of the presentation through the investor section of Septerna's website, where it will be available for replay for at least 30 days.

Established to push the boundaries in GPCR research, Septerna combines a talented team of experts in GPCR and drug development. The company’s proprietary Native Complex Platform® enables innovative strategies for GPCR drug discovery and has facilitated the creation of a diverse pipeline of novel oral small molecule drug candidates. Septerna is targeting significant therapeutic areas, including endocrinology, immunology and inflammation, and metabolic diseases, among others. The company engages in both independent development of its programs and strategic partnerships, making it well-positioned to address substantial unmet medical needs.

As the biotechnology landscape continues to evolve, Septerna's dedication to advancing GPCR therapies showcases its commitment to transformative healthcare solutions. Investors and stakeholders are encouraged to monitor the presentation for insights into Septerna’s progress and future directions. Further information about the company and its initiatives can be found on their website at www.septerna.com. For investor inquiries, Renee Leck can be contacted via email, while media inquiries can be directed to Carly Scaduto, both representatives of the consulting firm THRUST.

As Septerna, Inc. prepares to present at the TD Cowen 46th Annual Health Care Conference, investors should closely watch this event, given the company's unique positioning in the biotech landscape and its focus on G protein-coupled receptor (GPCR) drug discovery. With its proprietary Native Complex Platform®, Septerna is poised to revolutionize therapeutic approaches for various medical conditions, including significant unmet needs in endocrinology, immunology, and metabolic diseases.

One of the key focal points for investors will be the details shared about Septerna's current clinical pipeline, the specificity of its drug candidates, and any new data or advancements that could strengthen its market position. The ability to successfully navigate GPCR target opportunities can lead to substantial growth, particularly as recent data suggests a renewed interest and investment in GPCR-related therapies. Investors should pay attention to insights regarding collaborations and partnerships, which could enhance the speed and breadth of Septerna's developments in the pipeline.

It is also important for investors to consider market responses to announcements made during the presentation. Clear articulation of competitive advantages, such as reduced timeframes for drug development and improved patient outcomes, could generate heightened interest and boost the company's stock volatility post-presentation.

Furthermore, understanding the broader market dynamics in the biotech sector—including investor appetite for clinical-stage companies and trends in healthcare investments—will provide necessary context for evaluating Septerna's future. As they showcase their capabilities in a robust conference setting, investors should gauge management's commitment to innovation and the strategic vision laid out by CEO Jeffrey Finer. Overall, a detailed assessment of Septerna's pipeline developments and strategic partnerships during the presentation will be crucial for informed investment decisions moving forward.